HR6837

HR6837 amends the Employee Retirement Income Security Act of 1974 (ERISA) to explicitly classify Pharmacy Benefit Managers (PBMs) as fiduciaries for group health plans. This change imposes a legal duty on PBMs to act solely in the best interest of the plans and their beneficiaries. The bill also mandates comprehensive disclosure of all direct and indirect compensation PBMs receive, including rebates, fees, and discounts from drug manufacturers, distributors, and other third parties. This eliminates the current opaque business model where PBMs often profit from spread pricing and undisclosed rebates, forcing them into a transparent, service-fee-based structure. The money trail for PBMs currently involves significant revenue generated from the difference between what they charge health plans and what they pay pharmacies, as well as retained rebates from drug manufacturers. Under this bill, these revenue streams become transparent and subject to fiduciary scrutiny, meaning PBMs can no longer retain these funds without explicit disclosure and justification as being in the plan's best interest. This shifts billions of dollars in potential savings back to group health plans and their beneficiaries, directly reducing the top-line revenue and profit margins of PBMs. Historically, increased transparency and regulation in healthcare services have compressed margins for intermediaries. For example, when the Affordable Care Act (ACA) introduced medical loss ratio (MLR) requirements in 2010, health insurers were forced to spend a minimum percentage of premium revenue on medical care, limiting administrative costs and profit. While not directly comparable, the principle of regulatory intervention to control healthcare costs by targeting intermediary profits is consistent. The market reacted by pressuring health insurer stocks, though the long-term impact was absorbed through business model adjustments. This PBM legislation is more direct in targeting specific revenue streams. Specific companies that stand to lose significantly are the major PBMs: CVS Health ($CVS) through its Caremark segment, Cigna ($CI) through Express Scripts, Elevance Health ($ELV) through CarelonRx, and UnitedHealth Group ($UNH) through OptumRx. These companies derive substantial revenue from their PBM operations, which rely on the current opaque pricing and rebate structures. The imposition of fiduciary duties and mandatory disclosures will directly reduce their profitability from these segments. Conversely, group health plans and their beneficiaries will gain from increased transparency and potentially lower prescription drug costs.